EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas
Launched by MEDIGENE · Sep 18, 2006
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Inoperable adenocarcinoma of the pancreas
- • Histologic or cytologic confirmation
- • At least 18 years of age
- Exclusion Criteria:
- • Any chemotherapeutical treatment for pancreatic adenocarcinoma before enrollment
- • Major surgery within 4 weeks prior to enrollment
- • Major cardiovascular disease
About Medigene
Medigene AG is a leading clinical-stage biotechnology company focused on the development of innovative immunotherapies for the treatment of cancer. With a strong emphasis on harnessing the power of the immune system, Medigene is pioneering the discovery and commercialization of personalized T-cell therapies, including its proprietary dendritic cell vaccines and T-cell receptor (TCR) technologies. The company is committed to advancing its robust pipeline through rigorous clinical trials, aiming to provide effective therapeutic options that enhance patient outcomes and quality of life in oncology. Medigene's expertise in immunology and cell therapy positions it at the forefront of the rapidly evolving landscape of cancer treatment.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kiev, , Ukraine
Budapest, , Hungary
Prague, , Czech Republic
Patients applied
Trial Officials
Matthias Löhr, Prof.
Principal Investigator
Universitätsklinikum Mannheim
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials